Programs & Events

The Science of Market Development

Presented in Cooperation with Dymedex Consulting

4/7/2010

Bookmark and Share




Time

Registration: 7:00 am - 8:00 am
Program: 8:00 am - 5:00 pm

Event Description

Only 12% of medical technologies generate significant returns to their investors, and 50% fail outright.
-''Patient Capital: How Venture Capital Investment Drives Revolutionary Medical Innovation,'' National Venture Capital Association's Medical Industry Group. www.nvca.org

Navigating a medical technology to achieve its full commercial potential with limited resources is a significant challenge. In such a complex market, management must usually rely on incomplete and imperfect information to guide critical decision making.

Dymedex Consulting has developed unique methods for reducing uncertainty and enhancing your odds of commercial success. They have personally orchestrated over 100 unique medical technology adoption assessments in more than 20 different geographies. Based on this pioneering work, Dymedex has identified and statistically validated the factors that predict failure of - and drive rapid success of - medical technologies.

This course content is applicable to all medical technologies whether they are at the concept stage, newly released, struggling to grow, or seemingly on the fast track.

''Innovative and disciplined approach to a critical element of emerging growth businesses that goes to the foundation of resource prioritization, investment, expectations and outcomes.''
Bob Paulson - CEO, NxThera


Attendees will learn specific techniques and insights that have been proven to enable better strategic decision making:
• Defining (and addressing) the key barriers to adoption that constrain higher growth rates
• Quickly recognizing the unavoidable boundaries that limit a market opportunity
• Understanding which technology characteristics can radically influence physician adoption
• Synthesizing high level variables to create more accurate revenue forecasts
• Quantifying trade-offs across investment options and their impact on revenue growth

The intended audience for this one-day in-depth program includes seasoned medical device/technology marketing and market development managers, and senior leaders of small to medium size medical device companies. Anyone responsible for setting strategic direction and delivering top-line performance in uncertain markets will benefit from this content-rich program.

Speakers

Joseph L. Galatowitsch, President & Managing Partner, Dymedex Consulting; Ross Meisner, Managing Director, Dymedex Consulting

Joseph L. Galatowitsch has over 26 years of experience in medical business management, marketing and market development. At 3M Joe held a number of strategic, marketing, and (more)

Ross Meisner has over 18 years experience building technology companies, six in the medical device industry. He founded or co-founded four start-up companies and (more)

Topics

The following topics will be addressed:

  • Special Feature

Location

Radisson Hotel & Conference Center, Plymouth Directions

Emergo July 09 Devicix 2010 GMI ad 2010 CardioTec ad 2010